Ecliptasaponin A

Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors^{[1][2][3][4][5][6][7]}. In Vitro:Ecliptasaponin A (5-20 μM) inhibits the HMGB1/TLR4/NF-κB pathway to play a protective role on H9C2 cells of oxygen-glucose deprivation (OGD)^[3].
Ecliptasaponin A (0-120 μM, 24-48 h) exhibits dose- and time-dependent inhibition of H460 and H1975 cells viability and colony formation ability^[4].
Ecliptasaponin A (0-30 μM, 24 h) induces apoptosis through the activation of ASK1/JNK pathway and autophagy in H460 and H1975 cells^[4].
Ecliptasaponin A (5-30 μM, 48 h) inhibits ECM and MMP13 expression in human kidney-2 (HK-2) cells induced by transforming growth factor-beta1 (TGFβ1)^[5].
Ecliptasaponin A (0-25 μM) targets the protein ESR1 to increase the viability and reduce apoptosis in Cyclophosphamide (HY-17420)-induced damage in AW-CCH252 cells^[6].
Ecliptasaponin A (10-50 ng/mL, 25 h) shows the reduced expression of all osteoarthritis -related molecules in IL-1β-stimulated SW1353 cells^[7].
In Vivo:Ecliptasaponin A (1-18 g/kg, p.o., single dose) is distributed in various tissues, with the concentration order being: liver > spleen > lung > kidney > heart^[1].
Ecliptasaponin A (80 mg/kg, p.o., once daily for 28 days) prevents the fibrosis in mice via inhibiting TGF-β1 expression^[2].
Ecliptasaponin A (0.5-2.5 mg/kg, intramyocardial injection of the left ventricular myocardium, single dose) demonstrates a cardiac protective role in acute myocardial infarction (AMI) model in mice^[3].
Ecliptasaponin A (25-50 mg/kg, i.p., for 21 days) causes a clear suppression of tumor growth in lung cancer-bearing nude mice^[4].
Ecliptasaponin A (80 mg/kg, p.o., once daily for 10 days) reduces the renal collagen fiber deposition and renal extracellular matrix (ECM) protein expression in renal fibrosis unilateral ureteral obstruction (UUO) mice^[5].
Ecliptasaponin A (200 mg/mL with Specnuezhenide (HY-N0665), p.o., once daily for 30 days) improves the basal characteristics and sex hormone levels premature ovarian failure (POF) mice^[6].